Optimizing Breast Cancer Management

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Gradishar, William J. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2018.
• Έκδοση: 1st ed. 2018.
• Σειρά: Cancer Treatment and Research, 173
• Θέματα: Oncology .; Gynecology .; Radiotherapy.; Oncology.; Gynecology.

 This book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice. It also explores the controversy regarding mammography screening and reviews the contribution of new imaging modalities. Considerable attention is paid to developments in surgical procedures, including the potential for the safe and effective use of sentinel lymph node dissection alone-even in patients with positive nodes-and to the advantages and contraindications of new radiotherapy techniques. Genetic aspects are discussed in detail, including an assessment of the role of genetic testing and the potential impact of genetic signatures on breast cancer management. New systemic strategies, such as anti-HER2 therapy, endocrine agents, and agents to reverse endocrine resistance, are considered, and the optimal use of chemotherapy for early-stage and advanced-stage disease is addressed. In closing, the book shares important new insights into lifestyle risk factors, risk reduction strategies, and survivor issues, including sexual dysfunction and fertility maintenance. 

 Strategies to maintain fertility in young breast cancer patients -- Sexual dysfuncton in breast cancer survivors -- The breast cancer screening conundrum -- New Imaging modalities in breast cancer -- Is DCIS over treated -- "Personalizing" Breast Radiation -- Management of the axilla in early stage breast cancer -- Management of the breast in denovo MBC -- Identification of genetic lesions in patients with strong family history and no BRCA Mutation -- Managing "testing expectations" in breast cancer survivors -- The role of bone strengthening agents in early and advanced disease -- Overcoming endocrine resistance -- Optimal Adjuvant endocrine therapy -- Choosing wisely in HER2 positive metastatic breast cancer -- Should early stage, triple negative breast cancer be treated with preoperative systemic therapy?